Clinical trials: Ranibizumab
Subfoveal Choroidal Neovascularization
Comparative Study With Photodynamic Therapy And Triamcinolone Versus Photodynamic Therapy, Triamcinolone And Ranibizumab In Patients With Subfoveal Choroidal Neovascularization
The purpose of this study is to compare the efficacy of photodynamic therapy with verteporfin (PDT) and IVTA vs triple therapy (TT) in patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular…
- Trial name
- NCT00930189
- Testing
- intravitreal injection of ranibizumab, intravitreal injection of triamcinolone, photodynamic therapy
- Where
- Mexico
- Volunteers
- healthy volunteers welcome
- Sponsor
- Asociación para Evitar la Ceguera en México
Retinal Hemorrhage, Macular Degeneration
Subretinal Lucentis for Hemorrhagic Age-related Macular Degeneration (AMD)
Visual outcomes of the eye with large subretinal hemorrhages (bleeding under the retina) due to Age-Related Macular Degeneration (AMD) are poor.
- Trial name
- NCT00538538
- Testing
- vitrectomy with subretinal lucentis
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Corewell Health East
Age-Related Macular Degeneration
Genetic Analysis of Patients Responsive to Ranibizumab But Resistant to Aflibercept
A cohort of patients responsive to treatment with ranibizumab but resistant to aflibercept were identified in a previously conducted retrospective study. Identified patients will have their blood drawn for genome wide sequencing.
- Trial name
- NCT02291887
- Testing
- Ranibizumab, Aflibercept
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Associated Retinal Consultants, Michigan
Macular Degeneration, Choroidal Neovascularization
Enhancing the Lucentis (Ranibizumab) Management of Choroidal Neovascular Membranes With Hyperspectral Imaging
Clinical trial investigating the role of hyperspectral imaging in the management of patients undergoing standard clinical treatment for naive neovascular choroidal membranes in age-related macular degeneration.
- Trial name
- NCT03105609
- Testing
- Hyperspectral imaging
- Where
- Australia
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Center for Eye Research Australia
Ischemia, Retinal Vein Occlusion
Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2)
The RAVE 2 trial is a phase I, open label, 12-month trial of intravitreal ranibizumab 2.0 mg in patients with ischemic CRVO who have been either previously treated with ranibizumab or treatment naïve.
- Conditions
- Ischemia, Retinal Vein Occlusion, Pathologic Processes, Retinal Diseases
- Trial name
- RAVE2 (NCT01225146)
- Testing
- ranibizumab
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- David M. Brown, M.D.
Diabetic Macular Edema
Ranibizumab For Persistent Diabetic Macular Edema After Bevacizumab
This is an open-label, Phase I/II study of Intravitreally administered 0.3mg ranibizumab in subjects with persistent Diabetic Macular Edema (DME) after recent and frequent bevacizumab (at least 2 bevacizumab intravitreal…
- Trial name
- ROTATE (NCT01845844)
- Testing
- Ranibizumab 0.3mg/0.05cc
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Southeast Retina Center, Georgia
Macular Degeneration, Choroidal Neovascularization
Evaluation of Dosing Interval of Higher Doses of Ranibizumab
Evaluation of Dosing Interval of Higher Doses of Ranibizumab for patients with wet age-related macular degeneration (AMD).
- Trial name
- BGB/IST (NCT00533520)
- Testing
- ranibizumab
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Brandon G. Busbee, MD
Diabetic Macular Edema
IAI for Persistent DME After Treatment With Bevacizumab And Ranibizumab
This is a phase 4 prospective, nonrandomized, open label, interventional clinical trial. Study eyes will receive 5 required initial monthly Intravitreal Aflibercept (IAI) doses of 2 mg followed by 2q8 IAI for a total of 52 weeks…
- Trial name
- ROTATED (NCT03340610)
- Testing
- Alflibercept
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Southeast Retina Center, Georgia
Recalcitrant Wet Age-related Macular Degeneration
Ranibizumab for Recalcitrant Wet Age-related Macular Degeneration in Eyes Previously Switched From Bevacizumab and/or Ranibizumab to Aflibercept.
The purpose of the study is to determine the effectiveness of Ranibizumab 0.5 mg or 1.0 mg in subjects who were previously treated with Bevacizumab and subsequently switched to Aflibercept.
- Trial name
- RESCUE (NCT01972763)
- Testing
- Ranibizumab
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Northern California Retina Vitreous Associates
Wet AMD
Investigates Improvement in Vision Following Switching From Avastin and Macugen Over to Lucentis
The purpose of this study is to determine whether people who have received intermittent anti-VEGF therapy have an improvement in vision after being switched to monthly injections of Lucentis.
- Trial name
- NCT00804934
- Testing
- Lucentis
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Retina Institute of Hawaii
Angioid Streaks
Ranibizumab Therapy for Choroidal Neovascularization (CNV) Asociated With Angioid Streaks
The purpose of this study is to determine whether injections of ranibizumab into the eye are safe and well tolerated when given to subjects in multiple doses.
- Trial name
- NCT01015495
- Testing
- ranibizumab
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Illinois Chicago
Glaucoma, Rubeosis Iridis
Intravitreal Aflibercept or Ranibizumab for Rubeosis Iridis
Aflibercept (Eylea®) and ranibizumab (Lucentis®) are an anti-VEGF, but there are differences between the two drugs. To determine and compare whether intraocular aflibercept and ranibizumab decreases rubeosis iridis (RI) in…
- Trial name
- NCT02641457
- Testing
- Aflibercept, Ranibizumab
- Where
- Brazil
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Instituto de Olhos de Goiania
Choroidal Neovascularization
Safety Study of Ranibizumab Eye Injections to Treat Choroidal Neovascularization That Was Caused Other Than by Age-Related Macular Degeneration.
The purpose of this study is to determine whether ranibizumab is effective in the treatment of choroidal neovascularization secondary to causes other then wet macular-degeneration.
- Trial name
- NCT00395551
- Testing
- ranibizumab
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Ophthalmic Consultants of Boston
Diabetic Retinopathy, Macular Edema
Dosing Study of Ranibizumab for Diabetic Retinal and Macular Edema
This study is to see whether treating diabetic retinal swelling with ranibizumab injections into the eye monthly is better than treating diabetic retinal swelling with ranibizumab injections into the eye less frequently.
- Trial name
- NCT01476449
- Testing
- Ranibizumab
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Retina Vitreous Associates of Florida
Ocular Histoplasmosis Syndrome
Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization in Ocular Histoplasmosis Syndrome
The purpose of this study is to evaluate the safety and effectiveness of intravitreal ranibizumab (Lucentis) in patients with fluid and blood leakage in their eyes due to ocular histoplasmosis.
- Trial name
- IVL for OHS (NCT00955630)
- Testing
- ranibizumab
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Retina Associates of Kentucky
Polypoidal Choroidal Vasculopathy
Ranibizumab for Polypoidal Choroidal Vasculopathy (PCV)
This is a 12 month study of monthly injections of ranibizumab in subjects with polypoidal choroidal vasculopathy as diagnosed by fluoresceins/indocyanine green (FA/ICG) angiography.
- Trial name
- PEARL (NCT00424710)
- Testing
- ranibizumab intravitreal injection
- Where
- 2 sites in United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Hawaii Pacific Health
Polypoidal Choroidal Vasculopathy
Safety Study of High-Dose Ranibizumab for Polypoidal Choroidal Vasculopathy
Monthly, continuous anti-vegf therapy for patients presenting with active polypoidal choroidal vasculopathy. Two arms, treatment naive and previously treated with an FDA approved anti-VEGF therapy, will be randomized and dosed…
- Trial name
- PEARL2 (NCT01248117)
- Testing
- ranibizumab 2.0mg
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Retina Consultants of Hawaii
Retinal Vein Occlusion, Macular Edema
Bevacizumab Versus Ranibizumab in Treatment of Macular Edema From Vein Occlusion
Antagonists of the vascular endothelial growth factor (VEGF) pathway are effective in treating macular edema resulting from retinal vein occlusion (RVO).
- Trial name
- CRAVE (NCT01428388)
- Testing
- Intravitreal injection of bevacizumab, Intravitreal injection of ranibizumab (0.5 mg per dose)
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Barnes Retina Institute
Retinal Vein Occlusion
Intravitreal Ranibizumab Treatment of Central Retinal Vein Occlusion With Macular Edema
The purpose of this study is to examine the effects of Lucentis for active Central Retinal Vein Occlusion with Macular Edema
- Trial name
- NCT00403039
- Testing
- Ranibizumab (Lucentis )
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Vitreous -Retina- Macula Consultants of New York
Venous Retinal Branch Occlusion, Central Retinal Vein Occlusion
Impact of Lucentis on Psychological Morbidity in Patients With Retinal Vein Occlusion
This is a prospective, single-center, non-randomized clinical study on the impact of intravitreally administered ranibizumab (Lucentis) treatment on vision-related functioning and emotional well-being in subjects with central or…
- Conditions
- Venous Retinal Branch Occlusion, Central Retinal Vein Occlusion, Retinal Vein Occlusion, Depression
- Trial name
- NCT01011374
- Testing
- ranibizumab (Lucentis)
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Retina Associates of Cleveland, Inc